Semaglutide
Pro Research Analysisby 
Searched over 200M research papers for "Semaglutide"
Semaglutide: Efficacy, Safety, and Clinical Applications
Introduction to Semaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes and obesity. It is available in both subcutaneous and oral formulations, offering flexibility in administration. This article synthesizes the latest research on semaglutide, focusing on its efficacy, safety, and clinical applications.
Efficacy of Semaglutide in Glycemic Control
Glycemic Control in Type 2 Diabetes
Semaglutide has demonstrated significant efficacy in improving glycemic control in patients with type 2 diabetes. In the SUSTAIN 1 trial, semaglutide monotherapy significantly reduced HbA1c levels compared to placebo, with reductions of 1.45% and 1.55% for the 0.5 mg and 1.0 mg doses, respectively5. Similarly, the SUSTAIN 2 trial showed that semaglutide was superior to sitagliptin in reducing HbA1c levels, with reductions of 1.3% and 1.6% for the 0.5 mg and 1.0 mg doses, respectively10.
Combination Therapy with SGLT-2 Inhibitors
The SUSTAIN 9 trial investigated the efficacy of semaglutide as an add-on to SGLT-2 inhibitor therapy in patients with inadequately controlled type 2 diabetes. The study found that adding semaglutide significantly improved glycemic control, with a reduction in HbA1c of 1.42% compared to placebo1.
Weight Management and Obesity
Weight Reduction in Type 2 Diabetes
Semaglutide has also been effective in promoting weight loss in patients with type 2 diabetes. The STEP 2 trial demonstrated that semaglutide 2.4 mg once weekly led to a significant reduction in body weight compared to placebo, with an average weight loss of 9.6%3.
Weight Loss in Non-Diabetic Individuals
In the STEP 1 trial, semaglutide 2.4 mg once weekly was evaluated in adults with obesity but without diabetes. The study found a substantial mean weight loss of 14.9% compared to 2.4% with placebo, highlighting its potential for weight management in a broader population4.
Cardiovascular Outcomes
Cardiovascular Safety
The cardiovascular safety of semaglutide was assessed in the SUSTAIN 6 trial, which included patients with type 2 diabetes at high cardiovascular risk. The study found that semaglutide significantly reduced the risk of cardiovascular events, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, confirming its noninferiority to placebo2.
Safety Profile of Semaglutide
Common Adverse Events
The most frequently reported adverse events associated with semaglutide are gastrointestinal in nature, including nausea and diarrhea. These side effects are generally mild to moderate and tend to subside over time9. In the SUSTAIN 1 trial, gastrointestinal adverse events were the primary reason for discontinuation, affecting 20% and 24% of patients in the 0.5 mg and 1.0 mg semaglutide groups, respectively5.
Specific Safety Concerns
Semaglutide has been associated with an increased risk of biliary disease, such as cholelithiasis. Additionally, there is a need for careful monitoring of patients with diabetic retinopathy, as rapid improvements in glycemic control can exacerbate existing retinopathy9. However, no unexpected safety issues have arisen, and the overall safety profile of semaglutide is similar to other GLP-1 receptor agonists9.
Conclusion
Semaglutide is a highly effective GLP-1 receptor agonist for the management of type 2 diabetes and obesity. It significantly improves glycemic control and promotes substantial weight loss, with a favorable cardiovascular safety profile. While gastrointestinal side effects are common, they are typically transient and manageable. Overall, semaglutide offers a valuable treatment option for patients with type 2 diabetes and those seeking weight management solutions.
Sources and full results
Most relevant research papers on this topic
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Semaglutide once weekly as an add-on to SGLT-2 inhibitor therapy significantly improves HbA1c levels and bodyweight in patients with inadequately controlled type 2 diabetes.
RCT
Large Human Trial
Highly CitedSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Semaglutide significantly lowers the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes at high cardiovascular risk, confirming its noninferiority.
RCTLarge Human Trial
Rigorous JournalHighly CitedSemaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Semaglutide 24 mg once a week effectively manages weight in adults with overweight or obesity and type 2 diabetes, with more patients achieving at least 5% weight reduction compared to placebo.
RCTLarge Human TrialRigorous JournalHighly CitedOnce-Weekly Semaglutide in Adults with Overweight or Obesity.
Once-weekly semaglutide at 2.4 mg, combined with lifestyle intervention, effectively achieved sustained, clinically relevant weight loss in overweight or obese adults.
RCTLarge Human TrialRigorous JournalHighly CitedEfficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Once-weekly semaglutide monotherapy effectively improves glycemic control in treatment-naive patients with type 2 diabetes, but may cause gastrointestinal adverse events.
RCTLarge Human TrialHighly CitedEfficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Oral semaglutide is effective and safe for patients with type 2 diabetes and moderate renal impairment, improving glucose control and bodyweight reduction.
RCTLarge Human TrialHighly CitedOnce-Weekly Semaglutide in Adolescents with Obesity.
Once-weekly semaglutide treatment combined with lifestyle intervention significantly reduced BMI in adolescents with obesity compared to lifestyle intervention alone.
RCTRigorous JournalHighly CitedSemaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Semaglutide 05 mg and 10 mg show similar HbA1c reduction compared to dulaglutide 075 mg and 15 mg, respectively, in patients with inadequately controlled type 2 diabetes.
RCTLarge Human TrialHighly CitedSafety of Semaglutide
Semaglutide has a favorable risk/benefit profile for type 2 diabetes patients, with mostly mild gastrointestinal disturbances and increased risk of biliary disease, but no unexpected safety issues.
Literature ReviewHighly CitedEfficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Once-weekly semaglutide is more effective and safe than once-daily sitagliptin for improving glycemic control in patients with type 2 diabetes inadequately controlled on metformin, thiazolidinediones, or both.
RCTLarge Human TrialHighly CitedTry another search
recruitment and hiring process
What is the ideal volume for strength training?
What is the impact of digital media on children's cognitive development and social skills?
What is the impact of climate change on GDP?
semi-structured interview
What is the level of phonological awareness in 5-year-old children who attend a private educational